MedTrace Logo

Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

NCT05331144 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2025-08-05

No results posted yet for this study

Summary

The purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease pathology (i.e., excessive brain amyloid and tau protein deposition) in older adults at high risk for memory decline or dementia.

Conditions

  • Cognitively Normal Older Adults
  • Hypertension
  • Subjective Cognitive Decline
  • Family History of Dementia

Interventions

DRUG

Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine)

Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine) will be used to treat high blood pressure. Additional antihypertensive medications may be used if needed.

OTHER

PCP

Participants will follow their PCP's recommendations for BP control.

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Texas Health Resources

    collaborator OTHER

  • Michigan State University

    collaborator OTHER

  • Rong Zhang

    lead OTHER

Principal Investigators

  • Rong Zhang, PhD · University of Texas Southwestern Medical Center

  • Wanpen Vongpatanasin, MD · University of Texas Southwestern Medical Center

  • David Zhu, PhD · Michigan State University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-25
Primary Completion
2027-06-01
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05331144 on ClinicalTrials.gov